Skip to main
REGN

Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

Regeneron Pharmaceuticals (REGN) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 32%
Buy 36%
Hold 32%
Sell 0%
Strong Sell 0%

Bulls say

Regeneron Pharmaceuticals is a company with a strong portfolio of marketed products and a promising pipeline targeting various diseases. Despite recent setbacks in clinical trials, the company's continued growth and strong partnerships with companies like Sanofi and Bayer indicate a positive outlook for future developments. Additionally, the company shows a commitment to sustainability and diversity, which could further bolster its reputation and success in the long run. With strategic collaborations and a diverse product portfolio, Regeneron shows potential for significant growth and potential in the biopharmaceutical industry.

Bears say

Regeneron Pharmaceuticals is facing short-term pressure, driven by the concentration of investor activity ahead of a recent readout. While the company has strong partnerships and commercial products, issues with a recent trial may hinder its pipeline potential. The company has also faced pricing and market share loss concerns for its main product, Eylea, and may see continued pressure in the near term unless significant external developments occur.

Regeneron Pharmaceuticals (REGN) has been analyzed by 22 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 36% recommend Buy, 32% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Regeneron Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Regeneron Pharmaceuticals (REGN) Forecast

Analysts have given Regeneron Pharmaceuticals (REGN) a Buy based on their latest research and market trends.

According to 22 analysts, Regeneron Pharmaceuticals (REGN) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $817.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $817.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Regeneron Pharmaceuticals (REGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.